Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website https://jmc.elmerpub.com

Case Report

Volume 16, Number 8, August 2025, pages 309-313

Pure Red Cell Aplasia After ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation Successfully Treated With Daratumumab: Report of Two Cases

Figure

↓  Figure 1. Curve of hemoglobin and reticulocytes values, and response to treatment with daratumumab. Changes in hemoglobin concentration (blue line, right y-axis) and absolute reticulocyte count (orange line, left y-axis) in a patient after allogeneic hematopoietic cell transplantation with ABO major incompatibility (case 2). The x-axis indicates days after transplantation. The black arrow marks the initiation of rituximab treatment, and the red arrow marks the initiation of daratumumab treatment. A marked increase in reticulocyte count and gradual recovery of hemoglobin were observed following daratumumab administration.
Figure 1.

Table

↓  Table 1. Clinical Summary of Two Patients Receiving Post-Transplantation Daratumumab for Anemia-Associated ABO Major Incompatibility
 
Case Age (years)/gender Diagnosis ABO (donor/recipient) TCI (intensity) Previous treatments Days post-HCT at daratumumab beginning No. of doses
EPO: erythropoietin; HCT: hematopoietic stem cell transplantation; MDS: myelodysplastic syndrome; TCI: transplant conditioning intensity.
1 46/F Chronic neutrophilic leukemia B+/O+ Intermediate EPO, rituximab +266 4
2 58/M MDS with excess blasts II A+/O+ Intermediate EPO, rituximab +194 4